Table 1

Demographic and non-adherence characteristics of patients with rheumatic diseases (n=858)

nNon-adherence
(%)
Pattern of non-adherenceAetiology of non-adherence
Dose reduction or increase in frequency (%)Irregular consumption (%)Complete discontinuation (%)Fear of the IS effect of medications (%)Fear of the referring to clinics and hospitals (%)Symptoms suggestive of COVID-19 (%)
Total number of patients85856 (6.5)17 (30.4)6 (10.7)33 (58.9)35 (62.5)5 (8.9)16 (28.5)
Diseases
 RA (%)396 (46.2)11 (2.8)1 (9.1)1 (9.1)9 (81.8)4 (36.4)1 (9.1)6 (54.5)
 SpA (%)139 (16.1)23 (16.5)7 (30.4)2 (8.7)14 (60.9)12 (52.2)3 (13)8 (34.8)
 SLE and APS (%)70 (8.2)2 (2.9)1 (50)01 (50)2 (100)00
 BD (%)64 (7.5)3 (4.7)01 (33.3)2 (66.7)3 (100)00
 Vasculitis (%)53 (6.2)1 (1.9)1 (100)001 (100)00
 UIA (%)51 (5.9)8 (15.7)2 (25)1 (12.5)5 (62.6)6 (75)1 (12.5)1 (12.5)
 IIM, SSc, SS and others (%)44 (5.1)4 (9.1)3 (75)01 (25)3 (75)01 (25)
 Others (%)41 (4.8)4 (9.8)2 (50)1 (25)1 (25)4 (100)00
Medications
 NSAIDs (%)92 (10.7)12 (13)4 (33.3)3 (25)5 (41.7)6 (50)2 (16.7)4 (33.3)
 Colchicine (%)7 (0.8)0000000
 GCs (%)469 (54.7)38 (8.1)10 (26.3)3 (7.9)25 (65.8)23 (60.5)2 (5.3)13 (34.2)
 Hydroxychloroquine (%)254 (36.7)12 (4.7)2 (16.7)2 (16.7)8 (66.7)8 (66.7)2 (16.7)2 (16.7)
 Sulfasalazine (%)72 (8.4)4 (5.6)02 (50)2 (50)4 (100)00
 Methotrexate (%)327 (38.1)33 (10.1)5 (15.2)028 (84.8)27 (81.8)2 (6.1)4 (12.1)
 Leflunomide (%)19 (2.2)1 (5.3)001 (100)1 (100)00
 Azathioprine (%)44 (5.1)2 (9.1)2 (100)002 (100)00
 Calcineurin inhibitors (%)11 (1.3)0000000
 Mycophenolate mofetil (%)42 (4.9)4 (9.5)004 (100)4 (100)00
 Cyclophosphamide (%)13 (1.5)0000000
 bDMARDs (%)82 (9.6)31 (37.8)5 (16.1)026 (83.9)13 (41.9)6 (19.4)12 (38.7)
  • APS, antiphospholipid syndrome; BD, Behcet’s disease; bDMARDs, biologic disease-modifying antirheumatic drugs; GCs, glucocorticoids; IIM, idiopathic inflammatory myopathies; IS, immunosuppressive; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, seronegative spondyloarthritis; SS, Sjogren’s syndrome; SSc, systemic sclerosis; UIA, undifferentiated inflammatory arthritis.